Preclinical characterization of CS1003, a novel clinical-stage PD-1 monoclonal antibody

被引：0
|
作者：
Li, Fu [1 ]
Li, Jingrong [1 ]
Yin, Ke [1 ]
Zhang, Juan [1 ]
Li, Zhenhu [1 ]
Lu, Liang [1 ]
Bao, Yuanwu [1 ]
Pu, Dan [1 ]
Qin, Zhen [1 ]
Zheng, Yong [2 ]
Yang, Baotian [2 ]
Li, Jing [2 ]
Wang, Xinzhong Jon [1 ]
机构：
[1] CStone Pharmaceut Co Ltd, Shanghai, Peoples R China
[2] Wuxi Biol Co Ltd, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-4121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4121
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical characterization of MGA012, a novel clinical-stage PD-1 monoclonal antibody
    La Motte-Mohs, Ross
    Shah, Kalpana
    Brown, Jennifer G.
    Alderson, Ralph F.
    Smith, Doug
    Gorlatov, Sergey
    Ciccarone, Valentina
    Tamura, James K.
    Li, Hua
    He, Leilei
    Vasanwala, Farha
    Rillema, Jill R.
    Licea, Monica
    Hill, Jessica
    Wolff, Christina
    Pascuccio, Massimiliano
    Chen, Francine Z.
    Chen, Yan
    De Costa, Anushka
    Easton, Ann
    Berezhnoy, Alexey
    Li, Jonathan
    Nordstrom, Jeffrey
    Koenig, Scott
    Bonvini, Ezio
    Johnson, Syd
    Moore, Paul A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [2] CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy
    Fu Li
    Jingrong Li
    Ke Yin
    Juan Zhang
    Zhen-hu Li
    Liang Lu
    Yuan-wu Bao
    Zhen Qin
    Yong Zheng
    Bao-tian Yang
    Jing Li
    Xinzhong Wang
    Acta Pharmacologica Sinica, 2021, 42 : 142 - 148
  • [3] CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy
    Li, Fu
    Li, Jingrong
    Yin, Ke
    Zhang, Juan
    Li, Zhen-hu
    Lu, Liang
    Bao, Yuan-wu
    Qin, Zhen
    Zheng, Yong
    Yang, Bao-tian
    Li, Jing
    Wang, Xinzhong
    ACTA PHARMACOLOGICA SINICA, 2021, 42 (01) : 142 - 148
  • [4] Preclinical characterization of GLS-010 (AB122): A fully humanized clinical-stage anti-PD-1 antibody
    Tan, Joanne B.
    Chen, Chris
    Chen, Kai
    Li, Guochun
    Li, Jing
    Liu, Jieying
    Singh, Hema
    Wang, Guoyong
    Yang, Baotian
    Zhang, Kristin
    Zhao, Xiaoning
    Zheng, Yong
    CANCER RESEARCH, 2018, 78 (13)
  • [5] Clinical-stage monitoring of adaptive tumor resistance to PD-1 checkpoint blockade
    Smalley, M.
    Shanthappa, B.
    Gertje, H.
    Lawson, M.
    Ulaganathan, B.
    Thayakumar, A.
    Maciejko, L.
    Radhakrishnan, P.
    Biswas, M.
    Thiyagarajan, S.
    Majumder, B.
    Gopinath, K.
    Babu, G.
    Goldman, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E4 - E5
  • [6] Expression and clinical significance of PD-1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD-1 monoclonal antibody
    Li, Ziwei
    Li, Bin
    Peng, Dan
    Xing, Haiyan
    Wang, Guanying
    Li, Pan
    Wang, Jiming
    Ye, George
    Chen, Jianhong
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2018, 52 (06) : 2079 - 2092
  • [7] Preclinical characterization of STRO-002, a clinical-stage anti-FolRa antibody-drug conjugate
    Yuan, Robert
    McGeehan, Andrew
    Zhou, Sihong
    Smith, Jennifer
    Moreira, Dayson
    Bajjuri, Krishna
    Cuong Tran
    Yin, Gang
    Yam, Alice
    Kiefel, Helena
    Li, Xiaofan
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [8] Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma
    Tan, M.
    Quintal, L.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (05) : 504 - 507
  • [9] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Cosman, R.
    Moore, M.
    Eek, R.
    Mant, A.
    Zielinski, R.
    Chan, L. S.
    Ma, Y.
    Zhang, Q.
    Yau, T.
    Aghmesheh, M.
    Tse, A. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S840 - S840
  • [10] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Yau, T.
    Cosman, R.
    Aghmesheh, M.
    Moore, M.
    Chan, S. L.
    Mant, A.
    Eek, R.
    Zielinski, R.
    Li, P.
    Wang, H.
    Ma, Y.
    Tse, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1437 - S1438
12345